multiple myeloma

Welcome.

The following presentation is from a satellite symposium presented by Answers and CME, held during the JADPRO Live 2026, titled Cell Mods in Action, Integrating New Clinical Evidence into Real-World Relapsed Refractory Multiple Myeloma Management.

To access the full program and supporting materials, and to claim your certificate, please visit the activity URL in the episode description.

This activity is supported through an educational grant from Bristol-Myers Squibb.

Hello, everyone, and welcome, and I'm Beth Faiman.

I'm from Cleveland Clinic in Cleveland, Ohio, and it is my honor to be here tonight presenting with Dr. Bodeja from the Myeloma Research Center in, actually, what do you call yourself? What is your title? Why don't you tell us? What do I call myself?

Jesus.

So I'm the Director of Myeloma Research.

Sometimes I was just too sick to travel.

I'd had a form of blood cancer called multiple myeloma for more than 22 years, and I've been through dozens of rounds of treatments and gone in and out of remission more times than I care to remember.

While treatable, multiple myeloma is not curable for most patients.

For years I tried to compartmentalize my illness.

I didn't pretend I wasn't sick or keep my condition a secret, but I didn't want to identify as a cancer patient.

But thanks to breakthroughs in the treatment of my illness, many of them approved, and probably enough only in the time since I learned I was sick, I had been living with my disease for more than two decades.

I talked about the physical challenges of living with cancer for such a long time, like bone pain.

Multiple myeloma causes lesions in the bones and the constant anxiety of wondering when my illness is going to resurface.

Right.

Finally, let's look at multiple myeloma.

This is a malignancy of the plasma cells.

Yes.

Eva, Eva.

"Multiple myeloma.

I have been on chemotherapy and immunotherapy for the past five years, which has, which has been changed many times since none of the concoctions will work.

I have several questions regarding therapies which are amend and treatment for this type of CFC and then all the" You're taking a lot of good stuff.

Yes.

And I don't-- I hope your kidneys are okay, 'cause that, you know, multiple myeloma, kidneys, bones, there can be problems like that.

So you've gotta do the same thing I just described, okay, to this person, to, to Omaru.

Okay, same thing.

In this episode, produced in coordination with Oncology Nursing News, Drs.

Beth Faiman and Sikandar Alawadi discussed how on-body subcutaneous administration methods could allow for select at-home treatment of therapies for patients with multiple myeloma.

In the final episode of a three-part series, Drs.

Feyman and Alawadi explained how they are integrating on-body administration isotuximab for subcutaneous injection into clinical practice following its July 2026 FDA approval.

And when eventually the study got completed, there was only a small number of patients who went through the at-home administration, and all of these were ex-US.

So none of the US patients got to that point or opted for it, etc.

So The protocol outlined very nicely what checks and balances had to be in place so that, in my opinion, if somebody has to go down that path, my understanding is that more physicians, more healthcare systems outside the US, especially in Europe, are considering that strongly, basically, because they already have some of that process for certain other drugs, like bortezomib for multiple myeloma, which is routinely administered at home to patients in Europe.

In the US, we don't have that at home, but if patients are to go down that path, There are checks and balances that have to be in place.

[on-hold music] For years, first relapse myeloma regimens have delivered just one to two years of progression-free survival and immunomodulatory drugs were dosed to the maximum tolerated dose.

Iberdomide, the first cell mod approved by the FDA and the first myeloma approval based on minimal residual disease negative status changes this narrative.

Hello, I'm Maggie Shaw, lead editor with AJMC, and welcome to a special Director's Cut episode of Managed Care Cast.

Today, we are speaking with Dr. Sagar Lonial, professor and chair of the Department of Hematology and Medical Oncology at Emory University School of Medicine, chief medical officer at Winship Cancer Institute, and lead investigator of the Phase 3 ExCALIBUR Trial, new findings from which he presented at the recent IMS 2026 annual meeting.

[on-hold music] If you can start, please, by just briefly introducing yourself and your work.

Yeah.

I'm Sagar Lonial from the Winship Cancer Institute of Emory University in Atlanta, Georgia, and I have for over 20 years worked on new drugs, new therapies in multiple myeloma.

Most patients now relapse on or after lenalidomide.

Welcome to this program entitled Data and Perspectives.

Investigators discuss the optimal management of relapsed refractory multiple myeloma, which is a CME accredited satellite symposium during the SOHO 2026 annual meeting.

We have a wonderful panel of faculty, including Drs.

Dimopoulos and Dr. Raje, and it's my pleasure to serve as the moderator.

As I mentioned, Dr. Dimopoulos is on our faculty.

He's professor and chair of the Plasma Cell Dysplasia Unit at the National and Cappadocian University of Athens.

We have Dr. Raje, who's the director of the Center for Multiple Myeloma and Plasma Cell Disorders at Massachusetts General Brigham Cancer Institute.

And I'll be serving as the moderator, Bob Orlowski, from right here in MD Anderson, where I'm the director of translational research for multiple myeloma.